ConductScience.org, home

Trial · NCT02373202

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDSarilumab 150 mg q2w + DMARDs15
Overall StudySTARTEDSarilumab 200 mg q2w + DMARDs15
Overall StudySTARTEDSarilumab 150 mg q2w30
Overall StudySTARTEDSarilumab 200 mg q2w31
Overall StudyCOMPLETEDSarilumab 150 mg q2w + DMARDs13
Overall StudyCOMPLETEDSarilumab 200 mg q2w + DMARDs9
Overall StudyCOMPLETEDSarilumab 150 mg q2w27
Overall StudyCOMPLETEDSarilumab 200 mg q2w30
Overall StudyNOT COMPLETEDSarilumab 150 mg q2w + DMARDs2
Overall StudyNOT COMPLETEDSarilumab 200 mg q2w + DMARDs6
Overall StudyNOT COMPLETEDSarilumab 150 mg q2w3
Overall StudyNOT COMPLETEDSarilumab 200 mg q2w1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02373202/flow